TOTAL VOLUME:

$154.6b

24H VOL:

$333,432,169

24H TRANSACTIONS:

2,984,640,614

OPEN INTEREST:

$1,971,286,090

419,492

Markets across

40,634

events

MATCHED EVENTS:

4,654

PLATFORM COVERAGE:

5

Polymarket:

37%

VS.

Kalshi:

63%

BETA
Dashboards
Insights
Indices
API
Tour
All
Trending
Breaking
New
Ending Soon
Politics
Sports
Elections
Crypto
Companies
Financials
Economics
Other
Entertainment
Science and Technology
Will Johnson & Johnson (JNJ) Q3 MedTech revenue be above __?
polymarket

Will JNJ Q3 MedTech revenue be above?

Volume:
$4,554

$8.6B

 - Polymarket

$8.6B - Polymarket

1W

News

Positive

Negative

Neutral

Hover marker for details

Vol.

·

Resolved Oct 13, 2026

Closed: Oct 13, 8:24 AM EST

polymarket

Polymarket

View
Outcome
Trade
Chance %
Price
Spread
Liquidity
Volume
24h
7d
Open Interest
Ends in
Result
polymarket

$8.6B

View
100%
18%
Yes 100¢No 0¢
—
N/A
$253
N/A
N/A
N/A
Settled
Yes
polymarket

$8.9B

View
0%
22%
Yes 0¢No 100¢
—
N/A
$1,630
N/A
N/A
N/A
Settled
No
polymarket

$8.8B

View
0%
Yes 0¢No 100¢
—
N/A
$1,426
N/A
N/A
N/A
Settled
No
polymarket

$8.7B

View
0%
63%
Yes 0¢No 100¢
—
N/A
$1,055
N/A
N/A
N/A
Settled
No
polymarket

$9B

View
0%
18%
Yes 0¢No 100¢
—
N/A
$190
N/A
N/A
N/A
Settled
No
Total markets: 5

Description

This market will resolve to "Yes" if Johnson & Johnson's MedTech revenue for the upcoming third fiscal quarter, as reported in its official company earnings materials, is above the listed amount. Otherwise, this market will resolve to "No". The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered. If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No". If the specified company does not release quarterly earnings materials for the specified quarter by November 30, 2026, 11:59 PM ET, this market will resolve to "No". If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market. The resolution source for this market is Johnson & Johnson's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used. Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.

Polymarket

This market will resolve to "Yes" if Johnson & Johnson's MedTech revenue for the upcoming third fiscal quarter, as reported in its official company earnings materials, is above the listed amount. Otherwise, this market will resolve to "No". The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered. If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No". If the specified company does not release quarterly earnings materials for the specified quarter by November 30, 2026, 11:59 PM ET, this market will resolve to "No". If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market. The resolution source for this market is Johnson & Johnson's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used. Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.

Frequently asked questions

On Polymarket, the dashboard for the JNJ MedTech revenue market tracks the current odds of JNJ’s Q3 MedTech revenue exceeding a certain threshold. You’ll find a price history chart showing how the market has priced in this possibility over time, as well as the 24-hour trading volume, currently at $1,504. The total volume traded on this market is $4,554. This allows users to gauge market sentiment and activity surrounding the anticipated performance of Johnson & Johnson’s MedTech segment.

Currently, the prediction market suggests a strong likelihood that JNJ’s Q3 MedTech revenue will exceed expectations, as reflected in the odds displayed on Polymarket. This contrasts with traditional analyst forecasts, which often represent a single point estimate. The collective wisdom of the crowd, as expressed through this market, can offer a different perspective on the potential outcome. It’s important to remember that analyst forecasts and prediction market probabilities both represent informed opinions, but they are derived through different methodologies and may therefore diverge.

This market resolves around Oct 13, 2026, with the outcome confirmed once the official Q3 MedTech revenue figures from Johnson & Johnson are released and verifiable from credible public reporting. The resolution will be based on the reported revenue numbers, determining whether they fall above or below the target threshold. Traders who correctly predicted the outcome will be paid out according to the final market price, while those who predicted incorrectly will forfeit their stake. The market’s resolution is dependent on the official data released by the company.

Several signals could influence this market before it resolves. Any news regarding Johnson & Johnson’s MedTech product pipeline, regulatory approvals, or major contract wins or losses could significantly shift trader sentiment. Broader economic indicators, particularly those related to the healthcare sector, could also play a role. Unexpected announcements from competitors or changes in overall market conditions could also impact the price of shares in this market. Monitoring these factors will be key to understanding potential movements in the odds.